【14th.Sept.】Practical Asymmetric Syntheses of Complex Drug Targets
日期：2016-09-14
阅读：520
TOPIC：Practical Asymmetric Syntheses of Complex Drug Targets
SPEAKER：Dr. Chengyi Chen，Scientific Advisor/Scientific Director/External CROs and CMO Manager at Janssen Pharmaceutical Companies of Johnson & Johnson
TIME：September 14（Wednesday）AM10:00
LOCATION：Room 528, Chemistry Building A (化学A楼528演讲厅)
INVITER：张书宇 特别研究员
Abstract:
Asymmetric synthesis plays a crucial role in the contemporary drug discovery and development since many drugs are launched as chiral molecules. One of the key challenges for the asymmetric synthesis of drug substances is the efficient stereocontrol for the establishement of the desired chiral centers. The catalytic asymmetric reactions are highly desirable for these asymmetric syntheses since only a catalytic amount of expensive reagents/catalysts needs to be employed. In this presentation, a few novel catalytic asymmetric transformations will be illustrated for the synthesis of several structurally complex drug targets.
Biography:
Dr. Chengyi Chen has received his bachelor degree in chemistry from Xiamen University in 1984 and did his doctorate in Ohio State University with prof. David J. Hart until 1990. Then he joined in Janssen Pharmaceutical Companies of Johnson & Johnson. In 2000, he worked as senior investigator/associate director inprocessresearch department of Merck & Co. Inc. Laboratories (Montreal, Canada, Rahway, USA). Then he became senior principal scientist/distinguished senior investigator, process chemistry scientific/project lead in project chemistry and scientific advisor for process chemistry in at Merck & Co. Inc. Research Laboratories (Rahway, USA) from 2005-2014. In 2014, he worked as scientific advisor/scientific director/external CROs and CMO Manager at Janssen Pharmaceutical Companies of Johnson & Johnson (Schaffhausen, Switzerland). He has been focusing on designing, developing and implementing innovative, robust, cost-effective and green manufacturing routes to small molecule APIs. And he has become an industry-recognized expert in the design and development of manufacturing routes to significant drugs and late stage clinical candidates including Esketamine, Canagliflozin, Odalasvir, Cozaar, Maxalt, Sustiva, Januvia, Taranabant, Odanacatib, Omarigliptin, Elbasvir, Vaniprevir, and Doravirine. Until now, he has been the author of >90 publications/patents and invited lecturer for 70 presentations in main stream organic chemistry conferences and universities.
